Blocking TWEAK in pancreatic cancer cell lines resulted in a 22–65% cell growth inhibition of these cells, highlighting the therapeutic potential of this specific TNFR ligand in pancreatic cancer [14]. This evidence concerns the gene TNFRSF1A and familial pancreatic carcinoma.